Benjamin Hohl Sells 814 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 814 shares of the stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $30.00, for a total value of $24,420.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Friday, October 4th, Benjamin Hohl sold 10,218 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.51, for a total transaction of $281,097.18.
• On Monday, October 7th, Benjamin Hohl sold 1,270 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.51, for a total value of $34,937.70.
• On Friday, September 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.27, for a total value of $103,147.50.
• On Monday, September 30th, Benjamin Hohl sold 2,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.33, for a total transaction of $50,660.00.
• On Tuesday, August 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.54, for a total transaction of $95,795.00.
• On Wednesday, July 31st, Benjamin Hohl sold 991 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.53, for a total transaction of $27,282.23.
• On Monday, July 29th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $26.68, for a total transaction of $140,070.00.

Enliven Therapeutics Stock Up 0.3 %

NASDAQ:ELVN traded up $0.08 on Tuesday, reaching $28.95. The stock had a trading volume of 152,952 shares, compared to its average volume of 260,665. The company has a market capitalization of $1.36 billion, a P/E ratio of -14.96 and a beta of 1.10. The stock has a fifty day moving average price of $24.23 and a 200-day moving average price of $22.77. Enliven Therapeutics, Inc. has a 1-year low of $9.80 and a 1-year high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.17. Sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Enliven Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ELVN. First Turn Management LLC acquired a new position in shares of Enliven Therapeutics during the second quarter valued at $9,657,000. Janus Henderson Group PLC increased its stake in Enliven Therapeutics by 74.8% in the first quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock valued at $12,604,000 after purchasing an additional 305,397 shares in the last quarter. Marshall Wace LLP acquired a new stake in Enliven Therapeutics during the 2nd quarter worth $4,489,000. Baker BROS. Advisors LP acquired a new position in shares of Enliven Therapeutics in the 1st quarter valued at approximately $2,020,000. Finally, Nicholas Investment Partners LP bought a new stake in shares of Enliven Therapeutics during the second quarter worth $1,310,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $37.00 target price on shares of Enliven Therapeutics in a report on Tuesday, October 1st.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.